Detalles de la búsqueda
1.
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Haematologica
; 104(10): 2061-2074, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30846494
2.
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood
; 118(16): 4359-62, 2011 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21860025
3.
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Am J Hematol
; 87(3): 277-83, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22190165
4.
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Am J Hematol
; 85(9): 675-86, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20652971
5.
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.
Exp Hematol
; 36(5): 568-76, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18346839
6.
Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma.
Oncotarget
; 9(77): 34582-34594, 2018 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30349651
7.
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Oncotarget
; 7(35): 56253-56265, 2016 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27494845
8.
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Leuk Res
; 38(11): 1358-66, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25282334
9.
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
PLoS One
; 7(11): e50005, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23185517
10.
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Blood
; 104(4): 1159-65, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15130943
11.
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
Br J Haematol
; 123(2): 305-8, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-14531913
Resultados
1 -
11
de 11
1
Próxima >
>>